|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBE2H |
Gene summary for UBE2H |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBE2H | Gene ID | 7328 |
| Gene name | ubiquitin conjugating enzyme E2 H | |
| Gene Alias | E2-20K | |
| Cytomap | 7q32.2 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | P62256 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7328 | UBE2H | CA_HPV_1 | Human | Cervix | CC | 2.65e-05 | -2.67e-01 | 0.0264 |
| 7328 | UBE2H | CCI_2 | Human | Cervix | CC | 5.30e-07 | 1.12e+00 | 0.5249 |
| 7328 | UBE2H | H2 | Human | Cervix | HSIL_HPV | 2.22e-06 | 3.83e-01 | 0.0632 |
| 7328 | UBE2H | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.36e-04 | 5.96e-01 | 0.281 |
| 7328 | UBE2H | A015-C-203 | Human | Colorectum | FAP | 4.02e-26 | -3.79e-01 | -0.1294 |
| 7328 | UBE2H | A015-C-204 | Human | Colorectum | FAP | 3.46e-02 | -1.02e-01 | -0.0228 |
| 7328 | UBE2H | A014-C-040 | Human | Colorectum | FAP | 1.00e-03 | -2.42e-01 | -0.1184 |
| 7328 | UBE2H | A002-C-201 | Human | Colorectum | FAP | 1.52e-09 | -1.80e-01 | 0.0324 |
| 7328 | UBE2H | A002-C-203 | Human | Colorectum | FAP | 8.94e-03 | 1.63e-01 | 0.2786 |
| 7328 | UBE2H | A001-C-119 | Human | Colorectum | FAP | 2.99e-06 | 1.58e-01 | -0.1557 |
| 7328 | UBE2H | A001-C-108 | Human | Colorectum | FAP | 1.66e-13 | -1.07e-01 | -0.0272 |
| 7328 | UBE2H | A002-C-205 | Human | Colorectum | FAP | 6.87e-18 | -3.49e-01 | -0.1236 |
| 7328 | UBE2H | A015-C-006 | Human | Colorectum | FAP | 5.30e-13 | -4.30e-01 | -0.0994 |
| 7328 | UBE2H | A015-C-106 | Human | Colorectum | FAP | 2.34e-08 | -1.39e-01 | -0.0511 |
| 7328 | UBE2H | A002-C-114 | Human | Colorectum | FAP | 3.31e-17 | -3.37e-01 | -0.1561 |
| 7328 | UBE2H | A015-C-104 | Human | Colorectum | FAP | 1.55e-26 | -3.03e-01 | -0.1899 |
| 7328 | UBE2H | A001-C-014 | Human | Colorectum | FAP | 4.32e-14 | -1.30e-01 | 0.0135 |
| 7328 | UBE2H | A002-C-016 | Human | Colorectum | FAP | 4.88e-18 | -2.07e-01 | 0.0521 |
| 7328 | UBE2H | A015-C-002 | Human | Colorectum | FAP | 7.47e-11 | -3.89e-01 | -0.0763 |
| 7328 | UBE2H | A001-C-203 | Human | Colorectum | FAP | 6.38e-08 | -1.17e-01 | -0.0481 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
| GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
| GO:00002097 | Cervix | CC | protein polyubiquitination | 58/2311 | 236/18723 | 1.57e-07 | 7.41e-06 | 58 |
| GO:00709366 | Cervix | CC | protein K48-linked ubiquitination | 22/2311 | 65/18723 | 5.56e-06 | 1.38e-04 | 22 |
| GO:007093613 | Cervix | HSIL_HPV | protein K48-linked ubiquitination | 8/737 | 65/18723 | 3.86e-03 | 3.35e-02 | 8 |
| GO:00104982 | Colorectum | MSS | proteasomal protein catabolic process | 157/3467 | 490/18723 | 2.39e-13 | 5.25e-11 | 157 |
| GO:00431612 | Colorectum | MSS | proteasome-mediated ubiquitin-dependent protein catabolic process | 127/3467 | 412/18723 | 7.70e-10 | 6.32e-08 | 127 |
| GO:00002092 | Colorectum | MSS | protein polyubiquitination | 72/3467 | 236/18723 | 5.19e-06 | 1.42e-04 | 72 |
| GO:00709361 | Colorectum | MSS | protein K48-linked ubiquitination | 27/3467 | 65/18723 | 1.40e-05 | 3.18e-04 | 27 |
| GO:00431614 | Colorectum | FAP | proteasome-mediated ubiquitin-dependent protein catabolic process | 98/2622 | 412/18723 | 5.41e-08 | 4.20e-06 | 98 |
| GO:00104984 | Colorectum | FAP | proteasomal protein catabolic process | 110/2622 | 490/18723 | 2.12e-07 | 1.26e-05 | 110 |
| GO:00709362 | Colorectum | FAP | protein K48-linked ubiquitination | 24/2622 | 65/18723 | 3.42e-06 | 1.23e-04 | 24 |
| GO:00002093 | Colorectum | FAP | protein polyubiquitination | 59/2622 | 236/18723 | 4.53e-06 | 1.52e-04 | 59 |
| GO:00709363 | Colorectum | CRC | protein K48-linked ubiquitination | 19/2078 | 65/18723 | 5.34e-05 | 1.22e-03 | 19 |
| GO:00002094 | Colorectum | CRC | protein polyubiquitination | 46/2078 | 236/18723 | 9.91e-05 | 1.98e-03 | 46 |
| GO:00431615 | Colorectum | CRC | proteasome-mediated ubiquitin-dependent protein catabolic process | 69/2078 | 412/18723 | 3.16e-04 | 4.90e-03 | 69 |
| GO:00104985 | Colorectum | CRC | proteasomal protein catabolic process | 77/2078 | 490/18723 | 1.03e-03 | 1.21e-02 | 77 |
| GO:001049816 | Endometrium | AEH | proteasomal protein catabolic process | 108/2100 | 490/18723 | 2.73e-12 | 4.67e-10 | 108 |
| GO:004316116 | Endometrium | AEH | proteasome-mediated ubiquitin-dependent protein catabolic process | 88/2100 | 412/18723 | 1.54e-09 | 1.36e-07 | 88 |
| GO:00709367 | Endometrium | AEH | protein K48-linked ubiquitination | 21/2100 | 65/18723 | 4.56e-06 | 1.18e-04 | 21 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
| hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
| hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
| hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
| hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
| hsa041207 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
| hsa041208 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
| hsa041209 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
| hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
| hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
| hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
| hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
| hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
| hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
| hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
| hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
| hsa0412021 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
| hsa0412031 | Liver | Cirrhotic | Ubiquitin mediated proteolysis | 72/2530 | 142/8465 | 1.32e-07 | 1.97e-06 | 1.21e-06 | 72 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBE2H | SNV | Missense_Mutation | c.487N>A | p.Asp163Asn | p.D163N | P62256 | protein_coding | tolerated(0.09) | benign(0.024) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| UBE2H | SNV | Missense_Mutation | rs778682033 | c.523G>A | p.Glu175Lys | p.E175K | P62256 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UBE2H | SNV | Missense_Mutation | novel | c.58N>A | p.Glu20Lys | p.E20K | P62256 | protein_coding | tolerated(0.64) | benign(0.441) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UBE2H | SNV | Missense_Mutation | novel | c.537N>T | p.Gln179His | p.Q179H | P62256 | protein_coding | deleterious(0.02) | benign(0.365) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UBE2H | SNV | Missense_Mutation | novel | c.398N>A | p.Arg133Gln | p.R133Q | P62256 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UBE2H | SNV | Missense_Mutation | novel | c.449N>G | p.Thr150Arg | p.T150R | P62256 | protein_coding | deleterious(0.05) | probably_damaging(0.945) | TCGA-DD-AAEG-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| UBE2H | SNV | Missense_Mutation | novel | c.161N>T | p.Arg54Ile | p.R54I | P62256 | protein_coding | deleterious(0) | probably_damaging(0.92) | TCGA-49-AAR4-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxol | PD |
| UBE2H | SNV | Missense_Mutation | novel | c.296N>G | p.Tyr99Cys | p.Y99C | P62256 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-85-8354-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| UBE2H | SNV | Missense_Mutation | rs778682033 | c.523N>A | p.Glu175Lys | p.E175K | P62256 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-85-A4CL-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| UBE2H | SNV | Missense_Mutation | c.370N>A | p.Gly124Ser | p.G124S | P62256 | protein_coding | tolerated(0.13) | benign(0.101) | TCGA-CG-4305-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |